

Date: 03 Feb 2023
To: "Christian Chapa" christian.chapa@uacj.mx
cc: "Jessica Victoria Martínez Saraoz" al168456@alumnos.uacj.mx, "Jorge Alberto Roacho Pérez" alberto.roachoprz@uanl.edu.mx, "Imelda Olivas Armendáriz" iolivas@uacj.mx
From: "" melbert.munieza@springer.com
Subject: Your Submission DJPS-D-22-00643R2

Dear Dr. Chapa,

On the basis of our Specialty Associate Editor advice along with comments of the reviewers, I am pleased to inform you that your manuscript, "Lipid nanoparticles for gene therapy in ocular diseases", has been accepted for publication in DARU Journal of Pharmaceutical Sciences.

You will receive an e-mail in due course regarding the production process.

Please remember to quote the manuscript number, DJPS-D-22-00643R2, whenever inquiring about your manuscript.

With kind regards,
Mohammad Abdollahi, PharmD, PhD, FIAS, FAACT
Editor in Chief
DARU Journal of Pharmaceutical Sciences

Please note that this journal is a Transformative Journal (TJ). Authors may publish their research with us through the traditional subscription access route or make their paper immediately open access through payment of an article-processing charge (APC). Authors will not be required to make a final decision about access to their article until it has been accepted.

Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route our standard licensing terms will need to be accepted, including our self-archiving policies. Those standard licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.

Find out more about compliance

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/djps/login.asp?a=r>). Please contact the publication office if you have any questions.